Completed PHASE1 INTERVENTIONAL 7-arm NCT01949909

Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib (P27A)

Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A With Alhydrogel® Or GLA-SE As Adjuvant: A Staggered, Antigen And Adjuvant Dose-Finding, Randomized, Multi-Centre Phase Ia/Ib Trial

Sponsor: Centre Hospitalier Universitaire Vaudois

Conditions Malaria

Interventions CH-Alum50 CH-GLA2.5/50 TZ Alum 50 TZ GLA 2.5/10 TZ GLA2.5/50 TZ GLA5/50 TZ Ver

Updated 7 times since 2017 Last updated: Jul 16, 2018 Started: Mar 31, 2014 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01949909, this PHASE1 trial focuses on Malaria and remains completed. Sponsored by Centre Hospitalier Universitaire Vaudois, it has been updated 7 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Oct 2021 [monthly]

Completed PHASE1
Aug 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier Universitaire Vaudois
European Vaccine Initiative
European and Developing Countries Clinical Trials Partnership (EDCTP)

Data source: Centre Hospitalier Universitaire Vaudois

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bagamoyo, Tanzania
• Lausanne, Switzerland